Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma

This is an open-label, randomized, phase II study to evaluate the clinical activity of pembrolizumab in combination with pazopanib compared to pazopanib monotherapy.

Trial Details

NCT ID
NCT05679921
Phase
PHASE2
Sponsor
Yonsei University
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • pembrolizumab, pazopanib
Locations (sample)
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Histologically confirmed Soft Tissue Sarcoma(STS) progression to 1 or 2 (less than 3) prior chemotherapy : Exclude pazopanib-resistant subtype - em…
  • Age \> 19 years, ≤80 years at time of study entry
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (within 7 days before screening)
  • Measurable disease by Response Evaluation Criteria in Solid Tumors Version 1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →